Cowen Reiterates Outperform Rating on Axsome Therapeutics (AXSM), Analyst Remains Optimistic for Approval of AXS-05, Sees 100-125% Upside
Tweet Send to a Friend
Cowen analyst Joseph Thome reiterated an Outperform rating and $120.00 price target on Axsome Therapeutics (NASDAQ: AXSM), following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
